The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
Open accessAbstract
BACKGROUND: MYD88(L265P) and CXCR4(WHIM) mutations are highly prevalent in Waldenström's macroglobulinemia. MYD88(L265P) triggers tumor-cell growth through Bruton's tyrosine kinase, a target of ibrutinib. CXCR4(WHIM) mutations confer in vitro resistance to ibrutinib. METHODS: We performed a prospective study of ibrutinib in 63 symptomatic patients with Waldenström's macroglobulinemia who had received at least one previous treatment, and we investigated the effect of MYD88 and CXCR4 mutations on outcomes. Ibrutinib at a daily dose of 420 mg was administered orally until disease progression or the development of unacceptable toxic effects. RESULTS: After the patients received ibrutinib, median serum IgM levels decreased from 3520 mg per deciliter to 880 mg per deciliter, median hemoglobin levels increased from 10.5 g per deciliter to 13.8 g per deciliter, and bone marrow involvement decreased from 60% to 25% (P<0.01 for all comparisons). The median time to at least a minor response was 4 weeks. The overall response rate was 90.5%, and the major response rate was 73.0%; these rates were highest among patients with MYD88(L265P)CXCR4(WT) (with WT indicating wild-type) (100% overall response rate and 91.2% major response rate), followed by patients with MYD88(L265P)CXCR4(WHIM) (85.7% and 61.9%, respectively) and patients with MYD88(WT)CXCR4(WT) (71.4% and 28.6%). The estimated 2-year progression-free and overall survival rates among all patients were 69.1% and 95.2%, respectively. Treatment-related toxic effects of grade 2 or higher included neutropenia (in 22% of the patients) and thrombocytopenia (in 14%), which were more common in heavily pretreated patients; postprocedural bleeding (in 3%); epistaxis associated with the use of fish-oil supplements (in 3%); and atrial fibrillation associated with a history of arrhythmia (5%). CONCLUSIONS: Ibrutinib was highly active, associated with durable responses, and safe in pretreated patients with Waldenström's macroglobulinemia. MYD88 and CXCR4 mutation status affected responses to this drug. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01614821.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citationIbrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Self-citationMYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
Treon, S. P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Sheehy, P., Manning, R. J., Patterson, C. J., Tripsas, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200710 · Cited by 1,294
Self-citationAdvani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
Self-citationOwen, R. G., Treon, S. P., Al-Katib, A., Fonseca, R., Greipp, P. R., McMaster, M. L., Morra, E., Pangalis, G. A., San Miguel, J. F., Branagan, A. R., et al. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50082 · Cited by 924
Self-citationde Rooij, M. F. M., Kuil, A., Geest, C. R., Eldering, E., Chang, B. Y., Buggy, J. J., Pals, S. T., & Spaargaren, M. (2012) · Blood · doi:10.1182/blood-2011-11-390989 · Cited by 554
Hunter, Z. R., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Manning, R. J., Tripsas, C., Patterson, C. J., Sheehy, P., et al. (2014) · Blood · doi:10.1182/blood-2013-09-525808 · Cited by 488
Self-citationInternational prognostic scoring system for Waldenström macroglobulinemia
Morel, P., Duhamel, A., Gobbi, P., Dimopoulos, M. A., Dhodapkar, M. V., McCoy, J., Crowley, J., Ocio, E. M., Garcia-Sanz, R., Treon, S. P., et al. (2009) · Blood · doi:10.1182/blood-2008-08-174961 · Cited by 416
Self-citationXu, L., Hunter, Z. R., Yang, G., Zhou, Y., Cao, Y., Liu, X., Morra, E., Trojani, A., Greco, A., Arcaini, L., et al. (2013) · Blood · doi:10.1182/blood-2012-09-454355 · Cited by 414
Self-citationTreon, S. P., Cao, Y., Xu, L., Yang, G., Liu, X., & Hunter, Z. R. (2014) · Blood · doi:10.1182/blood-2014-01-550905 · Cited by 388
Self-citationYang, G., Zhou, Y., Liu, X., Xu, L., Cao, Y., Manning, R. J., Patterson, C. J., Buhrlage, S. J., Gray, N., Tai, Y.-T., et al. (2013) · Blood · doi:10.1182/blood-2012-12-475111 · Cited by 352
Self-citationHow I treat Waldenström macroglobulinemia
Treon, S. P. (2015) · Blood · doi:10.1182/blood-2015-01-553974 · Cited by 287
Self-citationJiménez, C., Sebastián, E., Chillón, C., Giraldo, P., Hernández, J. M., Escalante, F., González‐López, T. J., Aguilera, C., de Coca, A. G., Murillo, I., et al. (2013) · Leukemia · doi:10.1038/leu.2013.62 · Cited by 267
Treatment of Waldenström’s Macroglobulinemia With Rituximab
Dimopoulos, M. A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N. A., Grigoraki, V., Karkantaris, C., Mitsouli, C., Gika, D., Christakis, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.039 · Cited by 253
Lunn, M. P., & Nobile-Orazio, E. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002827.pub4 · Cited by 235
MYD88 L265P mutation in Waldenstrom macroglobulinemia
Poulain, S., Roumier, C., Decambron, A., Renneville, A., Herbaux, C., Bertrand, E., Tricot, S., Daudignon, A., Galiègue-Zouitina, S., Soenen, V., et al. (2013) · Blood · doi:10.1182/blood-2012-06-436329 · Cited by 235
Cao, Y., Hunter, Z. R., Liu, X., Xu, L., Yang, G., Chen, J., Patterson, C. J., Tsakmaklis, N., Kanan, S., Rodig, S., et al. (2015) · Leukemia · doi:10.1038/leu.2014.187 · Cited by 227
Self-citationPlacebo-controlled trial of rituximab in IgM anti-myelin–associated glycoprotein neuropathy
Léger, J.-M., Viala, K., Nicolas, G., Créange, A., Vallat, J.-M., Pouget, J., Clavelou, P., Vial, C., Steck, A., Musset, L., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e318296e92b · Cited by 208
Roccaro, A. M., Sacco, A., Jimenez, C., Maiso, P., Moschetta, M., Mishima, Y., Aljawai, Y., Sahin, I., Kuhne, M., Cardarelli, P., et al. (2014) · Blood · doi:10.1182/blood-2014-03-564583 · Cited by 207
Self-citationHerman, S. E. M., Niemann, C. U., Farooqui, M., Jones, J., Mustafa, R. Z., Lipsky, A., Saba, N., Martyr, S., Soto, S., Valdez, J., et al. (2014) · Leukemia · doi:10.1038/leu.2014.122 · Cited by 193
Chen, C. I., Kouroukis, C. T., White, D., Voralia, M., Stadtmauer, E., Stewart, A. K., Wright, J. J., Powers, J., Walsh, W., & Eisenhauer, E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8659 · Cited by 188
How I treat Waldenström macroglobulinemia
Treon, S. P. (2009) · Blood · doi:10.1182/blood-2009-05-174359 · Cited by 186
Self-citationStrauss, S. J., Maharaj, L., Hoare, S., Johnson, P. W., Radford, J. A., Vinnecombe, S., Millard, L., Rohatiner, A., Boral, A., Trehu, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6789 · Cited by 170
Dimopoulos, M. A., Kastritis, E., Owen, R. G., Kyle, R. A., Landgren, O., Morra, E., Leleu, X., García-Sanz, R., Munshi, N., Anderson, K. C., et al. (2014) · Blood · doi:10.1182/blood-2014-03-565135 · Cited by 169
Self-citationThe CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome
McDermott, D. H., Liu, Q., Ulrick, J., Kwatemaa, N., Anaya‐O’Brien, S., Penzak, S. R., Filho, J. O., Priel, D. A. L., Kelly, C., Garofalo, M. E., et al. (2011) · Blood · doi:10.1182/blood-2011-07-368084 · Cited by 151
SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia
Ngo, H. T., Leleu, X. P., Lee, J. Y., Jia, X., Melhem, M. R., Runnels, J. M., Moreau, A., Burwick, N. R., Azab, A. K., Roccaro, A. M., et al. (2008) · Blood · doi:10.1182/blood-2007-12-129395 · Cited by 130
Self-citationCao, Y., Hunter, Z. R., Liu, X., Xu, L., Yang, G., Chen, J., Tsakmaklis, N., Kanan, S., Castillo, J. J., & Treon, S. P. (2014) · British Journal of Haematology · doi:10.1111/bjh.13200 · Cited by 109
Self-citationXu, L., Hunter, Z. R., Yang, G., Cao, Y., Liu, X., Manning, R. J., Tripsas, C. K., Chen, J. G., Patterson, C. J., Kluk, M., et al. (2014) · Leukemia · doi:10.1038/leu.2014.65 · Cited by 103
Self-citationDotta, L., Tassone, L., & Badolato, R. (2011) · Current Molecular Medicine · doi:10.2174/156652411795677963 · Cited by 96
Transcription Factor STAT5A Is a Substrate of Bruton's Tyrosine Kinase in B Cells
Mahajan, S., Vassilev, A. O., Sun, N., Özer, Z., Mao, C., & Uckun, F. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104874200 · Cited by 65
Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., Devine, S. M., Djulbegović, B., Faber, E. A., Gasparetto, C., Hernandez‐Ilizaliturri, F. J., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0128 · Cited by 47
Self-citation
Cited by
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Role of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
Jäger, U., Barcellini, W., Broome, C. M., Gertz, M. A., Hill, A., Hill, Q. A., Jilma, B., Kuter, D. J., Michel, M., Montillo, M., et al. (2020) · Blood Reviews · doi:10.1016/j.blre.2019.100648 · Cited by 565
Tam, C. S., Opat, S., D'Sa, S., Jurczak, W., Lee, H.-P., Cull, G., Owen, R. G., Marlton, P., Wahlin, B. E., Sanz, R. G., et al. (2020) · Blood · doi:10.1182/blood.2020006844 · Cited by 466
Self-citationPirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Mato, A. R., Shah, N. N., Jurczak, W., Cheah, C. Y., Pagel, J. M., Woyach, J. A., Fakhri, B., Eyre, T. A., Lamanna, N., Patel, M. R., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00224-5 · Cited by 466
Self-citation
Metadata
- Authors
- Treon, S. P., Tripsas, C. K., Meid, K., Warren, D., Varma, G., Green, R., Argyropoulos, K. V., Yang, G., Cao, Y., Xu, L., Patterson, C. J., Rodig, S., Zehnder, J. L., Aster, J. C., Harris, N. L., Kanan, S., Ghobrial, I., Castillo, J. J., Laubach, J. P., Hunter, Z. R., Salman, Z., Li, J., Cheng, M., Clow, F., Graef, T., Palomba, M. L., & Advani, R. H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-09
- Volume
- 372
- Issue
- 15
- Pages
- 1430-1440
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2133192145
- Cited by
- 942
- References
- 32
- FWCI
- 57.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.